Impeller

Impel Capital and Sky Communications announce Strategic Partnership

Retrieved on: 
Tuesday, December 5, 2023
Impeller, Information technology, Partnership, Telecommunications

Herndon, Va., Dec. 5, 2023 /PRNewswire/ -- Through an affiliate of Impel Capital ("Impel"), a private equity firm focused on investing in lower middle-market companies supporting both the public and private sectors, announced today that it has entered into a strategic partnership with Sky Communications, Inc., ("SkyCom"), a long-standing telecommunications and information technology management firm.

Key Points: 
  • Herndon, Va., Dec. 5, 2023 /PRNewswire/ -- Through an affiliate of Impel Capital ("Impel"), a private equity firm focused on investing in lower middle-market companies supporting both the public and private sectors, announced today that it has entered into a strategic partnership with Sky Communications, Inc., ("SkyCom"), a long-standing telecommunications and information technology management firm.
  • Founded in 1996 and headquartered in Flower Mound, Texas, SkyCom provides IT Support and managed-services for clients across the country.
  • "We are pleased to have the opportunity to partner with a highly reputable company that has grown into a leader in the field."
  • I am very excited about SkyCom's partnership with Impel and this sets the stage for our next chapter", said Bill Bouie.

46 Leading Cloud Computing Companies, Products and Services

Retrieved on: 
Wednesday, September 20, 2023
Cloud, Impeller, EY, Television

PHILADELPHIA, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Today the Business Intelligence Group is proud to announce the winners of the 2023 Stratus Awards for Cloud Computing by recognizing 46 companies, services, and executives deemed leaders in the cloud.

Key Points: 
  • The Stratus Awards panel of judges also recommended that the following companies and services be recognized as "Finalists" for their documented performances.
  • Stratus Award Finalists include: Alteryx Analytics Cloud Platform, AuditBoard, Boomi, CoreStack, Cyera, Datasite Cloud, ECI Software Solutions, EY, Impel, Impetus, Jackrabbit Technologies, DevOps360, ADP®, Sibros, and Synadia Control Plane.

Impel Launches AI-Powered Virtual Photo Booth for Automotive Retailers and OEMs

Retrieved on: 
Thursday, September 14, 2023
Cars.com, Edmunds, Auto Trader, Original equipment manufacturer, SRP, Marketing, Computer vision, Image, AI, OEM, ROI, CarGurus, Online shopping, Camera, Impeller

SYRACUSE, N.Y., Sept. 14, 2023 /PRNewswire-PRWeb/ -- Impel, the global leader in AI-powered customer lifecycle management and digital merchandising for the automotive industry, announced today that it has released a fully-automated Virtual Photo Booth and Image Enhancement solution that enables dealers and OEMs to deliver branded, studio-grade vehicle photos and 360° walkarounds without investing in expensive physical booths. Powered by state-of-the-art Computer Vision AI technology, Impel's automated imaging solution optimizes image and video quality, removes background clutter, and ensures compliance with OEM-mandated imaging requirements.

Key Points: 
  • The company's AI-powered Virtual Booth technology delivers an authentic photo booth viewing experience without the need for capital investments, additional hardware or dedicated physical space.
  • Featuring a variety of adaptive 3-D backgrounds and customization options, Impel's Virtual Photo Booth provides a realistic studio environment that increases shopper engagement and establishes visual consistency across auto retailers' digital showrooms.
  • According to Erick Kirks, Marketing Director at Johnson Automotive Group, "For more than eight years, we've relied on Impel to support our dealerships with game-changing technology solutions that strengthen our brand.
  • With Impel's Virtual Booth, shoppers can explore every aspect of a vehicle in a rich and dynamic format from any digital device.

Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?

Retrieved on: 
Thursday, August 17, 2023
Migraine, Roa, Moa, COVID-19, Perception, Prescription, CGRP, Launch, Neurology, DHE, Projection, RealTime, Dihydroergotamine, Patient, Physician, Mall of America, FDA, Impeller, Nasal spray, First Ever, Pfizer, Pharmaceutical industry, Ubrogepant

Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.

Key Points: 
  • Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.
  • As of June, over three-quarters of physicians planned to prescribe Zavzpret to their migraine patients within the first six months of availability.
  • One way to tease apart the relative advantages and disadvantages of new migraine therapies is to utilize Spherix’s Launch Dynamix™: Zavzpret series.
  • Spherix will be tracking the awareness and perception of these investigational, pipeline therapies in its separate service, RealTime Dynamix™.

Impel Expands Automotive Digital Engagement Platform with Chat AI - An Automated Conversational Agent Powered by Generative AI

Retrieved on: 
Wednesday, June 28, 2023
LLM, Natural language processing, Communication, Hallucination, Original equipment manufacturer, Synthetic media, ChatGPT, Service, Intelligence, OpenAI, NLP, CRM, VIN, AI, OEM, Safety, Automation, Customer service, Online shopping, Sales, Impeller

SYRACUSE, N.Y., June 28, 2023 /PRNewswire-PRWeb/ -- Impel, the global leader in automotive digital engagement technology, announced today that it is launching Chat AI, an automated conversational agent powered by generative AI. Chat AI enables auto dealers and OEMs to engage shoppers with a fully automated conversational chat experience that delivers hyper-personalized, human-like responses to consumer questions. The company's newest application combines the natural language processing capabilities of generative AI and a mix of large language models (LLMs) with integrations and optimizations designed specifically for auto retailers. Chat AI is fully integrated with Impel's AI-powered communication suite, including Sales AI and Service AI.

Key Points: 
  • Chat AI enables auto dealers and OEMs to engage shoppers with a fully automated conversational chat experience that delivers hyper-personalized, human-like responses to consumer questions.
  • SYRACUSE, N.Y., June 28, 2023 /PRNewswire-PRWeb/ -- Impel , the global leader in automotive digital engagement technology, announced today that it is launching Chat AI, an automated conversational agent powered by generative AI.
  • Chat AI enables auto dealers and OEMs to engage shoppers with a fully automated conversational chat experience that delivers hyper-personalized, human-like responses to consumer questions.
  • Chat AI is fully integrated with Impel's AI-powered communication suite, including Sales AI and Service AI.

Impel Hires Former Cox Automotive Executive to Support International Expansion

Retrieved on: 
Tuesday, June 27, 2023
Partnership, Mannheim, International, Auto Trader, United Kingdom, Cox Enterprises, Growth, Car dealership, Video game, Impeller

LONDON, June 27, 2023 /PRNewswire/ -- Impel, the global leader in AI-powered digital engagement technology for the auto industry, announced today that it will begin direct operations in the United Kingdom and has hired James Leese as Sales Director. Leese joins Impel at a time of rapid growth for the company, and follows the Company's recent $104 million growth equity announcement.

Key Points: 
  • Leese joins Impel at a time of rapid growth for the company, and follows the Company's recent $104 million growth equity announcement .
  • Leese brings decades of automotive technology experience to Impel, most recently as Chief Customer Officer at Cox Automotive, Europe.
  • "We are thrilled to have James join Impel," said Ben Cooper, Managing Director, International at Impel.
  • This move will allow Impel to further scale its UK presence and provide additional customer support for new and existing clients in challenging market conditions.

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023
Migraine, SG, Marketing, AAN, IMPL, CINC, Prescription, American Academy, CGRP, AstraZeneca, Acquisition, Patient, Administration, Annual general meeting, Host, CPA, Webcast, Growth, Research and development, Research, R, Impeller, Conference, Safety, American Academy of Neurology, Mobile phone, Pharmaceutical industry, Health insurance, Dihydroergotamine

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • ET
    SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
  • ET today to discuss the first quarter 2023 financial results and provide a corporate and business update.
  • A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/ .
  • A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

Retrieved on: 
Wednesday, May 10, 2023
LLP, University at Albany, SUNY, University, Senior, IMPL, State university system, Business, Business school, State, AstraZeneca, Professional corporation, Business administration, Acquisition, School, CPA, Growth, Impeller, Ernst & Young, Management

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.

Key Points: 
  • SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.
  • “Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals,” said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals.
  • Prior to joining Impel Pharmaceuticals, he was Executive Vice President & Chief Financial Officer of CinCor Pharma, Inc., where he played an integral role in the company’s recent acquisition by AstraZeneca for up to $1.8 billion.
  • Mr. Kalb added, “I am thrilled to join Impel’s accomplished leadership team at such an important time in the Company’s evolution.

Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

Retrieved on: 
Friday, May 5, 2023
IMPL, Webcast, Impeller, Pharmaceutical industry, Online shopping

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m.

Key Points: 
  • SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m.
  • ET to report its first quarter 2023 financial results and provide a business update.
  • A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/ .
  • A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

At Eighteen Months Post-Launch, Impel's Trudhesa Has Struggled to Keep Up with Pfizer's Nurtec ODT and AbbVie's Ubrelvy, According to Spherix Global Insights

Retrieved on: 
Friday, April 14, 2023
NASA RealWorld-InWorld Engineering Design Challenge, Ubrogepant, Eli Lilly and Company, CGRP, Launch, Eli Lilly, Vomiting, AbbVie, Physician, Patient, Nausea, RealTime, Pharmaceutical industry, Lasmiditan, Dihydroergotamine, Migraine, Impeller, Pfizer

EXTON, Pa., April 14, 2023 /PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of Impel's Trudhesa for the acute treatment of migraines. At eighteen months post-launch, analysis reveals that Impel's brand has made consistent launch progress, now rivaling Eli Lilly's Reyvow, which has been in the market since January 2020. Trudhesa has achieved moderate ratings for familiarity, usage, satisfaction, likelihood to recommend, and overall risk/cost-benefit ratio.

Key Points: 
  • EXTON, Pa., April 14, 2023 /PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of Impel's Trudhesa for the acute treatment of migraines.
  • Trudhesa has achieved moderate ratings for familiarity, usage, satisfaction, likelihood to recommend, and overall risk/cost-benefit ratio.
  • This is most apparent in the latter stages of the launch as, according to surveyed physicians, future projected uptake estimates never fully materialized.
  • Further, Trudhesa uptake will continue to be tracked along with the broader migraine market via Spherix's RealTime Dynamix™ quarterly service.